New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:49 EDTAMAGAMAG sees FY13 COGS of between 14% and 18% of net product sales
AMAG sees FY13 cost of goods sold, COGS, of between 14% and 18% of net product sales; Total operating expenses, excluding COGS, of between $78M and $82M, representing an approximate 10% reduction from 2012. The reduced operating expenses in 2013 will be driven by decreased clinical trial costs, offset in part by new investments in a lower-cost production process and pre-launch investments to support a potential expansion to Feraheme’s label. The company expects: Research and development expenses of between $24M and $27M, representing an approximate 27% reduction from 2012; Selling, general and administrative expenses of between $54M and $57M, representing an approximate 2% increase from 2012.
News For AMAG From The Last 14 Days
Check below for free stories on AMAG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
10:05 EDTAMAGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:35 EDTAMAGAMAG Pharmaceuticals initiated with a Market Perform at FBR Capital
Subscribe for More Information
August 12, 2014
08:21 EDTAMAGAMAG Pharmaceuticals appoints Robert Blood as Chief Compliance Officer
Subscribe for More Information
August 7, 2014
14:16 EDTAMAGJames Flynn reports 5.99% passive stake in AMAG Pharmaceuticals
August 6, 2014
06:22 EDTAMAGJefferies to hold a summit
Boston Healthcare Summit to be held in Boston on August 6.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use